Shares of Shield Therapeutics plc (LON:STX – Get Free Report) were down 10.9% on Wednesday . The company traded as low as GBX 4.06 ($0.05) and last traded at GBX 4.10 ($0.05). Approximately 2,521,852 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 4,690,169 shares. The stock had previously closed at GBX 4.60 ($0.06).
Shield Therapeutics Stock Down 12.8 %
The company has a market cap of £31.36 million, a P/E ratio of -114.05 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The stock has a fifty day moving average price of GBX 4.32 and a two-hundred day moving average price of GBX 2.77.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Featured Articles
- Five stocks we like better than Shield Therapeutics
- What Are Dividend Achievers? An Introduction
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Dividend Payout Ratio Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
